Lakeside Holding (LSH) is pleased to announce that its wholly owned subsidiary, Hupan Pharmaceutical Co., has entered into two distribution agreements with Hubei Kelun Pharmaceutical Trading Co., Ltd., a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd., a publicly traded company on the Shenzhen Stock Exchange, principally engaged in the research and development, manufacture and distribution of pharmaceutical products. Under the agreements, Hupan Pharmaceutical will distribute basic large-volume parenteral solutions, along with related medical products and equipment, to healthcare institutions across China. The agreements, effective from January 1, 2025, to December 31, 2025, further expand Hupan Pharmaceutical’s portfolio of medical distribution clients.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LSH:
